Skip to content
Bepotastine
Bepreve (bepotastine) is a small molecule pharmaceutical. Bepotastine was first approved as Bepreve on 2009-09-08. It is used to treat allergic conjunctivitis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
immune system diseasesD007154
Trade Name
FDA
EMA
Bepreve (generic drugs available since 2019-03-05)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bepotastine besilate
Tradename
Company
Number
Date
Products
BEPREVEBausch Health CompaniesN-022288 RX2009-09-08
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
bepreveNew Drug Application2019-09-02
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
allergic conjunctivitisEFO_0007141D003233H10.44
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Bepotastine Besilate, Bepreve, Bausch And Lomb Inc
87847892025-01-13DP
88771682023-07-30DP
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
21 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic conjunctivitisD003233EFO_0007141H10.44—234—8
Allergic rhinitisD065631J30.91——1—2
HypersensitivityD006967EFO_0003785T78.40———1—1
CoughD003371HP_0012735R05———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic rhinitis perennialD012221EFO_1001417J30.89——3——3
DermatitisD003872HP_0011123L30.9——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Allergic rhinitis seasonalD006255EFO_0003956J3014———4
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—1————1
PruritusD011537HP_0000989L291————1
UrticariaD014581EFO_0005531L501————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameBEPOTASTINE
INNbepotastine
Description
Bepotastine is an ether that is (S)-(4-chlorophenyl)(pyridin-2-yl)methanol in which the hydroxyl hydrogen is substituted by a 1-(3-carboxypropyl)piperidin-4-yl group. A topical, selective and non-sedating histamine (H1) receptor antagonist used (as its benzenesulfonate salt) for treatment of itching associated with allergic conjunctivitis. It has a role as a H1-receptor antagonist and an anti-allergic agent. It is a member of pyridines, a monocarboxylic acid, a member of piperidines, an ether and a member of monochlorobenzenes. It is a conjugate base of a bepotastine(1+).
Classification
Small molecule
Drug classantihistaminics (histamine-H1 receptor antagonists)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1
Identifiers
PDB—
CAS-ID125602-71-3
RxCUI863035
ChEMBL IDCHEMBL1201758
ChEBI ID71204
PubChem CID164522
DrugBankDB04890
UNII IDHYD2U48IAS (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 169 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
288 adverse events reported
View more details